Filamentous Fungi Promoter Patents: Top Filers & Trends 2026
- Concentrated at the top. The five leading assignees together hold 41.4% of all 1,835 records in scope, with a further tail of single- and low-filing entrants.
- Filing has cooled from its 2019 peak. Annual output rose from 34 records in 2017 to a peak of 53 in 2019, then fell 40% between 2021 (42) and 2024 (25), the last year with complete data.
- Cellulase and xylanase constructs still anchor the influence graph. The most-cited records in the corpus are decades-old enzyme fusion and pentose-fermentation filings, a sign that current promoter work is still building on that base.
Filing growth compares 2021 (42 records) with 2024 (25) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,835 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent families addressing promoter engineering in filamentous fungal host cells — constructs governing inducible or constitutive transcription strength, operator sequences, promoter mutations and reporter-assay validation, filed against fungal expression systems used for enzyme and protein production. The scope spans 1,835 published records filed between 2015 and mid-2026, indexed under microorganism engineering, fermentation and nucleic-acid measurement classifications.
Because publication typically lags filing by around 18 months, the most recent one to two years in any trend understate real filing activity and should be read as provisional rather than a sign of decline.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Annual filing counts and IPC composition for the 1,835 records in scope, drawn directly from the underlying dataset.
Filing trend, 2017-2026
Filings climbed from 34 records in 2017 to a peak of 53 in 2019, then eased back; the 2021-to-2024 span shows a 40% decline (42 to 25 records), the last year clean of publication-lag distortion.
Technology composition by IPC subclass
C12N (microorganisms and genetic engineering) touches 97.3% of the 1,835 records, confirming this is fundamentally a host-organism engineering field; C12P (fermentation) and C07K (peptides/proteins) each cover roughly a third of records, and A23L (food applications) remains the smallest slice at 5.3%.
Shares are the percentage of the 1,835 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Filamentous Fungi Promoter Engineering with Eureka
This page is one run against one query. Ask Eureka your own question about filamentous fungi promoter engineering and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art in this space
US20060024782A1 — Production of a monoclonal antibody in a heterokaryon filamentous fungus or in a filamentous fungal host cell
The present invention relates to methods for producing a monoclonal antibody in a heterokaryon fungus or in a fungal host cell, using nucleic acid constructs encoding antibody light and heavy chains together with heterologous signal peptides for secretion from the fungal host.Filed by Novozymes A/S; published 2006-02-02.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2003062430A1 | Fermentation of pentose sugars | 666 |
| 2 | WO2006078256A2 | Polypeptides having xylanase activity and polynucleotides encoding same | 606 |
| 3 | WO2005093050A2 | Cellulase fusion protein and heterologous cellulase fusion construct encoding the same | 586 |
| 4 | WO1999031255A2 | Novel egiii-like enzymes, DNA encoding such enzymes and methods for producing such enzymes | 479 |
| 5 | WO2005093073A1 | EXO-endo cellulase fusion protein | 458 |
| 6 | US20150082478A1 | Plant genome modification using guide RNA/CAS endonuclease systems and methods of use | 433 |
| 7 | US5783431A | Methods for generating and screening novel metabolic pathways | 429 |
| 8 | WO2003052056A2 | Egviii endoglucanase and nucleic acids encoding the same | 421 |
| 9 | US5824485A | Methods for generating and screening novel metabolic pathways | 346 |
| 10 | WO2006009434A1 | Metabolic engineering of xylose fermenting eukaryotic cells | 312 |
Citation counts favour older filings simply because they have had longer to accumulate citations inside this searched corpus — read them as a signal of influence on later drafting, not as a ranking of current importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the filing trend, concentration figures and citation graph are read together.
A small group holds the core claim space
The five leading assignees account for 41.4% of all records in scope, and the ranked leaders extend to ten firms holding 52.1% combined. That leaves a long tail of entities with only a handful of filings each, typically covering narrower promoter variants or host-strain combinations the leaders have not claimed.
Output has pulled back from its 2019 high
Annual filings peaked at 53 in 2019 and declined to 25 by 2024, a 40% drop over the 2021-2024 window. This reads as a maturing claim space rather than an abandoned one — dense prior art around core promoter mechanisms raises the bar for new filings, it does not mean the underlying technology has stalled.
Enzyme-production art still anchors the field
The most-cited records in the corpus concern pentose fermentation and cellulase/xylanase fusion constructs, several with citation counts in the hundreds. Promoter-engineering filings routinely build on this enzyme-expression foundation, which is worth checking before assuming a promoter construct is entirely novel.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to filamentous fungi promoter engineering, with the prior art for and against each one.
The competitive landscape
Filing activity concentrates among a handful of industrial enzyme and biotech firms, with recent-year momentum cooling across the board.
The top assignee holds a clear lead
The leading assignee's 238 records sit well above fifth place at 81 and tenth place at 34, indicating a portfolio built over many years of continuation filing around core expression-system constructs.
A long tail below the leaders
Beyond the top ten, filing counts drop quickly; the ranked leaders is the full list the dataset returns, not a curated top-50 or top-100 cut, and most entities on it hold only a small handful of records each.
Even the leaders are filing less in the latest year
Several of the most active historical assignees show single-digit filing counts in the latest year with year-over-year declines in the -50% to -67% range, and others show zero. This is consistent with publication lag rather than necessarily a pullback in R&D investment.
| Assignee | Recent year | YoY |
|---|---|---|
| Danisco US Inc. | 1 | -67% |
| Novozymes A/S | 1 | -50% |
| Genencor International, Inc. | 0 | — |
| DSM IP Assets B.V. | 0 | — |
| Novozymes Inc. | 0 | — |
| E.I. du Pont de Nemours and Company (USA) | 0 | — |
| RYOGEN LLC | 0 | — |
| Gist-Brocades B.V. | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio benchmarking or identifying open filing space.
Map claim scope against the leading portfolios
With 41.4% of records held by five assignees, a freedom-to-operate check should start with those portfolios' independent claims on promoter structure and host-strain combinations before assuming open space.
Explore assignee portfolios in EurekaTrack the under-claimed branches
Reporter-assay standardisation and cross-species promoter portability show thinner direct coverage than the core constructs, making them worth a deeper prior-art pull before drafting.
Run a white-space search in EurekaWatch for the next filing wave once lag clears
2025-2026 filings are still being published; revisiting the trend in a year will show whether the 2021-2024 pullback continues or reverses.
Set up monitoring in EurekaCommon questions on this landscape
One assignee leads clearly with 238 records, well ahead of fifth place at 81 and tenth place at 34 in the ranked list. The top five assignees combined hold 41.4% of all 1,835 records in scope, and the top ten hold 52.1% combined. Beyond that, filing counts drop off quickly into a long tail of firms with only a handful of records each, so due diligence should focus first on the leading handful of portfolios.
Filings rose from 34 records in 2017 to a peak of 53 in 2019, then declined; the 2021-to-2024 window (the last span with complete data) shows a 40% drop, from 42 to 25 records. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by about 18 months, so it is too early to call the most recent years a continued decline. The honest read is a maturing filing pace after a 2019 peak, not a collapse.
C12N, covering microorganisms and genetic engineering, appears in 97.3% of the 1,835 records, confirming this is fundamentally a host-cell engineering field. C12P (fermentation and enzymatic synthesis) and C07K (peptides and proteins) each appear in roughly a third of records, reflecting the strong overlap with enzyme production. Because records can carry multiple IPC codes, these percentages add up to more than 100% and should not be summed.
US20060024782A1, assigned to Novozymes A/S, covers methods for producing a monoclonal antibody in a heterokaryon filamentous fungus or fungal host cell, using nucleic acid constructs encoding antibody light and heavy chains with heterologous signal peptides for secretion. Its blocking effect is specific to antibody-production constructs using this signal-peptide and dual-chain-construct architecture, not to fungal promoter engineering generally. Anyone designing an antibody-secretion system in a fungal host should review its exact claim scope closely rather than assuming it only affects enzyme-production work.
The most heavily claimed ground is core promoter mutation and inducible/constitutive control mechanisms tied to enzyme production, where the leading assignees already hold dense portfolios. Comparatively thinner coverage appears in cross-species promoter portability, standardised reporter-assay protocols for fungal hosts, and food-grade constitutive cassettes under A23L, which covers only 5.3% of records. These branches are worth a targeted prior-art search before drafting, since low record counts here reflect less direct claiming rather than technical impossibility.
Research Filamentous Fungi Promoter Engineering in depth with Eureka
Go past this page: query the whole filamentous fungi promoter engineering corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.